SCHEMBL6282949

SCHEMBL6282949

COc1ccc(-c2cc3ccncc3[nH]2)cc1NCc1cccc(O)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F3 P13726 5/20 0.45
KMT2A Q03164 3/20 0.42
ALDH1A1 P00352 2/20 0.42
MAPT P10636 2/20 0.42
KDM4E B2RXH2 1/20 0.42
LMNA P02545 1/20 0.42
HPGD P15428 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
RIPK1 Q13546 1/20 0.40
NR3C1 P04150 4/20 0.39
NR3C2 P08235 2/20 0.39
PI4KB Q9UBF8 1/20 0.39
PGR P06401 1/20 0.39
MEN1 O00255 2/20 0.39
HDAC8 Q9BY41 1/20 0.38
ROCK2 O75116 1/20 0.37
ROCK1 Q13464 1/20 0.37
SLC2A4 P14672 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6282806 0.93 F3 (0.53) F3KMT2AALDH1A1MAPTKDM4E
SCHEMBL6279135 0.89 KMT2A (0.44) F3KMT2AALDH1A1MAPTKDM4E
SCHEMBL6286928 0.88 SMN1; SMN2 (0.53) KMT2AALDH1A1MAPTKDM4ELMNA
SCHEMBL6287117 0.85 RIPK1 (0.59) KMT2AALDH1A1MAPTKDM4ELMNA
SCHEMBL6278579 0.84 KMT2A (0.41) F3KMT2AALDH1A1MAPTKDM4E
SCHEMBL6287129 0.84 RIPK1 (0.43) F3KMT2AALDH1A1MAPTKDM4E
SCHEMBL6286663 0.83 RIPK1 (0.42) F3KMT2AALDH1A1MAPTKDM4E
SCHEMBL6496194 0.83 MAPT (0.43) F3KMT2AALDH1A1MAPTKDM4E
SCHEMBL6285617 0.82 KMT2A (0.43) KMT2AALDH1A1MAPTKDM4ELMNA
SCHEMBL6282813 0.82 CCNB2 (0.56) KMT2AALDH1A1MAPTKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6943174-B2 6,5-Fused bicyclic heterocycles WARNER-LAMBERT COMPANY (US) 2005-09-13 US claimed
US-20040014759-A1 6,5-Fused bicyclic heterocycles PICARD JOSEPH ARMAND (US) 2004-01-22 US claimed
EP-1294718-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY LLC (US) 2003-03-26 EP claimed
WO-2001096336-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY (US) 2001-12-20 WO claimed
US-6943174-B2 6,5-Fused bicyclic heterocycles WARNER-LAMBERT COMPANY (US) 2005-09-13 US disclosed
US-20040014759-A1 6,5-Fused bicyclic heterocycles PICARD JOSEPH ARMAND (US) 2004-01-22 US disclosed
EP-1294718-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY LLC (US) 2003-03-26 EP disclosed
WO-2001096336-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY (US) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014759-A1 6,5-Fused bicyclic heterocycles ALOX15, ALOX5, ALOX15B F3 488/4885KMT2A 4200/4885ALDH1A1 522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.